Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CANFNASDAQ:CNATNASDAQ:LIXTNASDAQ:SONN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCANFCan-Fite BioPharma$1.07-0.9%$1.14$0.98▼$4.69$3.79M1.12235,573 shs38,950 shsCNATConatus Pharmaceuticals$0.02$1.00$0.23▼$1.07$587K1.841.28 million shs80 shsLIXTLixte Biotechnology$1.14-13.0%$1.27$0.98▼$3.00$3.06M0.37181,800 shs90,842 shsSONNSonnet BioTherapeutics$1.15-2.5%$1.26$1.08▼$13.65$3.64M0.94386,433 shs22,349 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCANFCan-Fite BioPharma0.00%-2.28%+2.39%-34.36%-65.92%CNATConatus Pharmaceuticals0.00%+1,375.00%-43.00%-41.00%-90.17%LIXTLixte Biotechnology0.00%-14.27%-20.83%-5.79%-55.81%SONNSonnet BioTherapeutics0.00%-8.00%-6.50%-15.74%-35.75%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCANFCan-Fite BioPharma3.2999 of 5 stars3.75.00.00.02.80.01.3CNATConatus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ALIXTLixte Biotechnology1.0221 of 5 stars0.05.00.00.03.00.80.0SONNSonnet BioTherapeutics2.8102 of 5 stars3.55.00.00.02.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCANFCan-Fite BioPharma 3.33Buy$14.001,208.41% UpsideCNATConatus Pharmaceuticals 0.00N/AN/AN/ALIXTLixte Biotechnology 0.00N/AN/AN/ASONNSonnet BioTherapeutics 3.00Buy$20.001,639.13% UpsideCurrent Analyst Ratings BreakdownLatest CNAT, CANF, LIXT, and SONN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/15/2025CANFCan-Fite BioPharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/7/2025SONNSonnet BioTherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/28/2025SONNSonnet BioTherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/18/2025CANFCan-Fite BioPharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCANFCan-Fite BioPharma$674K5.62N/AN/A$1.76 per share0.61CNATConatus Pharmaceuticals$21.72M0.03N/AN/A$0.53 per share0.03LIXTLixte BiotechnologyN/AN/AN/AN/A$0.22 per shareN/ASONNSonnet BioTherapeutics$1M3.64N/AN/A$1.32 per share0.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCANFCan-Fite BioPharma-$7.63M-$1.79N/AN/AN/AN/AN/AN/AN/ACNATConatus Pharmaceuticals-$11.39MN/AN/A∞N/A-52.42%-48.22%-39.32%N/ALIXTLixte Biotechnology-$5.09M-$1.45N/A∞N/AN/A-5,562.77%-130.48%8/6/2025 (Estimated)SONNSonnet BioTherapeutics-$7.44MN/A0.00∞N/AN/A-408.93%-174.13%8/13/2025 (Estimated)Latest CNAT, CANF, LIXT, and SONN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q2 2025SONNSonnet BioTherapeutics-$0.92-$0.89+$0.03-$0.89N/AN/A5/12/2025Q1 2025LIXTLixte BiotechnologyN/A-$0.29N/A-$0.29N/AN/A3/24/2025Q4 2024LIXTLixte BiotechnologyN/A-$0.27N/A-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCANFCan-Fite BioPharmaN/AN/AN/AN/AN/ACNATConatus PharmaceuticalsN/AN/AN/AN/AN/ALIXTLixte BiotechnologyN/AN/AN/AN/AN/ASONNSonnet BioTherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCANFCan-Fite BioPharmaN/A2.93N/ACNATConatus PharmaceuticalsN/A16.2816.28LIXTLixte BiotechnologyN/A5.135.13SONNSonnet BioTherapeuticsN/A2.152.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCANFCan-Fite BioPharma21.00%CNATConatus Pharmaceuticals15.20%LIXTLixte Biotechnology5.10%SONNSonnet BioTherapeutics9.45%Insider OwnershipCompanyInsider OwnershipCANFCan-Fite BioPharma0.80%CNATConatus Pharmaceuticals11.30%LIXTLixte Biotechnology14.80%SONNSonnet BioTherapeutics2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCANFCan-Fite BioPharma83.54 millionN/ANot OptionableCNATConatus Pharmaceuticals3033.17 millionN/ANot OptionableLIXTLixte Biotechnology42.68 million1.92 millionNot OptionableSONNSonnet BioTherapeutics103.17 million3.01 millionNot OptionableCNAT, CANF, LIXT, and SONN HeadlinesRecent News About These CompaniesFinancial Comparison: Madrigal Pharmaceuticals (NASDAQ:MDGL) & Sonnet BioTherapeutics (NASDAQ:SONN)June 12 at 1:29 AM | americanbankingnews.comsonnet biotherapeutics receives nasdaq delisting noticeJune 4, 2025 | investing.comSonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development SummitMay 1, 2025 | globenewswire.comSonnet Releases Virtual Investor "What This Means" SegmentApril 16, 2025 | globenewswire.comAir Traffic Controllers Lost Contact With Doomed Pilot Shortly After Takeoff: NTSBApril 11, 2025 | franklinreporter.comSonnet BioTherapeutics reports positive results from ovarian cancer therapy trialApril 7, 2025 | msn.comSonnet BioTherapeutics Reports Positive Phase 1b/2a Data For SON-1010April 6, 2025 | nasdaq.comSonnet BioTherapeutics advances in cancer trialApril 6, 2025 | uk.investing.comSonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at ...April 6, 2025 | seekingalpha.comSonnet Biotherapeutics Holdings Inc trading halted, news pendingApril 4, 2025 | markets.businessinsider.comSonnet says SON-1010 demonstrates ‘strong safety profile’ in atezolizumab comboApril 4, 2025 | markets.businessinsider.comSonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest DoseApril 4, 2025 | globenewswire.comSonnet BioTherapeutics appoints interim CEO and new presidentApril 3, 2025 | investing.comSonnet BioTherapeutics Names Raghu Rao Interim CEO As Founder PassesApril 3, 2025 | nasdaq.comPilot Killed In NJ Crash Was CEO Of Cancer-Focused Biotech CompanyApril 3, 2025 | msn.comDeadly plane crash in NJ neighborhood sounds like bomb explosionApril 2, 2025 | nj1015.comLawrenceville Man Piloted Plane That Crashed In Six Mile Run; Flight Lasted 5 MinutesApril 2, 2025 | franklinreporter.comPilot Killed In Franklin Twp Plane Crash Was CEO Of Cancer-Focused Biotech CompanyApril 2, 2025 | msn.comSonnet BioTherapeutics announces passing of founder, CEO Pankaj MohanApril 2, 2025 | markets.businessinsider.comSonnet Announces Release of Corporate Update VideoApril 1, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCNAT, CANF, LIXT, and SONN Company DescriptionsCan-Fite BioPharma NYSE:CANF$1.07 -0.01 (-0.93%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.07 0.00 (0.00%) As of 06/13/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.Conatus Pharmaceuticals NASDAQ:CNATConatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.Lixte Biotechnology NASDAQ:LIXT$1.14 -0.17 (-12.97%) Closing price 06/13/2025 03:58 PM EasternExtended Trading$1.14 +0.00 (+0.09%) As of 06/13/2025 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.Sonnet BioTherapeutics NASDAQ:SONN$1.15 -0.03 (-2.54%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$1.15 0.00 (0.00%) As of 06/13/2025 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
